Document Detail

Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
MedLine Citation:
PMID:  18434855     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the long-term efficacy and side effects of off-label topical tacrolimus 0.03% ointment (Protopic; Fujisawa Health, Deerfield, IL) as a sole second-line immunosuppressive agent in the management of high-risk corneal grafts. METHODS: Four consecutive patients underwent high-risk penetrating keratoplasty (4 grafts) with a prior diagnosis of corneal scar secondary to herpetic keratitis, keratoconus, acanthamoeba keratitis, and Fuchs endothelial dystrophy, respectively. All 4 patients developed steroid-induced glaucoma and failed traditional immunosuppressant therapy. Patients were started on topical tacrolimus ointment 0.03%, twice daily, which was tapered to the lowest possible therapeutic dose that maintained its antirejection efficacy. Patients were monitored for adverse treatment effects. The mean follow-up was 33 months (range, 26-48 months), and the mean treatment duration was 22.6 months (range, 13-32 months). RESULTS: All 4 high-risk corneal transplant patients experienced episodes of acute rejection that was successfully reversed with topical tacrolimus treatment. During tacrolimus treatment, there were no further episodes of graft rejection and no incidents of herpes simplex virus infection or reactivation, with the longest follow-up being 4 years. Two patients have been successfully tapered off tacrolimus, and 2 patients are currently on once-daily dosing. No adverse effects were observed. CONCLUSIONS: Topical tacrolimus 0.03% ointment seems to be a promising second-line immunosuppressant in management of high-risk grafts.
Jasmeet S Dhaliwal; Benjamin F Mason; Stephen C Kaufman
Related Documents :
22991015 - The effects of biocompatible compared with standard peritoneal dialysis solutions on pe...
2491465 - Cyclosporin for the treatment of severe inflammatory bowel disease.
18434855 - Long-term use of topical tacrolimus (fk506) in high-risk penetrating keratoplasty.
1769795 - Focal sclerosing glomerulopathy. risk factors of progression and optimal mode of treatm...
21944085 - The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: ...
15280195 - Peripheral blood stem cell transplantation in 16 patients with poems syndrome, and a re...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cornea     Volume:  27     ISSN:  0277-3740     ISO Abbreviation:  Cornea     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-24     Completed Date:  2008-06-16     Revised Date:  2009-06-24    
Medline Journal Info:
Nlm Unique ID:  8216186     Medline TA:  Cornea     Country:  United States    
Other Details:
Languages:  eng     Pagination:  488-93     Citation Subset:  IM    
Henry Ford Health System, Ophthalmology, Troy, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Follow-Up Studies
Glaucoma / chemically induced
Glucocorticoids / adverse effects
Graft Rejection / drug therapy*
Immunosuppressive Agents / therapeutic use*
Keratoplasty, Penetrating*
Middle Aged
Retrospective Studies
Risk Factors
Tacrolimus / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Glucocorticoids; 0/Immunosuppressive Agents; 0/Ointments; 109581-93-3/Tacrolimus
Comment In:
Cornea. 2009 Jul;28(6):715-6; author reply 716   [PMID:  19554675 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CLMI: the cone location and magnitude index.
Next Document:  Primary adenoid cystic carcinoma of the conjunctiva arising from the accessory lacrimal glands: a cl...